Feasibility of salkubatrovalsartan in the treatment of elderly patients with heart failure with reduced ejection fraction caused by ischemic cardiomyopathy
Objective To analyze the feasibility of salkubatrovalsartan in the treatment of elderly patients with heart failure with reduced ejection fraction(HFrEF)caused by ischemic cardiomyopathy.Methods A total of 108 patients with HFrEF caused by ischemic cardiomyopathy admitted in our hospital from August 2020 to August 2022 were selected as the study objects and divided into control group(n=54,treated with benazepril)and study group(n=54,treated with salkubatrovalsartan)according to the treatment plan.The therapeutic effects of the two groups were compared.Results The total effective rate of treatment in the study group was higher than that in the control group(P<0.05).After treatment,left ventricular end diastolic volume(LVEDV),left ventricular end diastolic diameter(LVEDD)and left ventricular posterior wall thickness(LVPW)decreased and left ventricular ejection fraction(LVEF)increased in both groups,and those in the study group were better than the control group(P<0.05).After treatment,the levels of N-terminal B-type natriuretic peptide precursor(NT-proBNP),galectin-3(Gal-3),soluble growth stimulation expressed gene 2(sST2),granulocyte-macrophage colony-stimulating factor(GM-CSF)and monocyte chemotactic protein-1(MCP-1)in both groups decreased,and those in the study group were lower than the control group(P<0.05).The total incidence of major adverse cardiovascular events(MACE)in the study group within 3 months of treatment was lower than that in the control group,and the number of hospitalization and the cumulative length of hospitalization were less than those in the control group(P<0.05).Conclusion Salkubatrovalsartan can improve the cardiac function and serum indexes of patients with HFrEF caused by ischemic cardiomyopathy,reduce the risk of MACE and number of hospitalization,with accurate short-term effect,which can be further promoted and applied in clinic.
salkubatrovalsartanheart failure with reduced ejection fractionischemic cardiomyopathy
NETL
NSTL
万方数据
维普
